* To replay the media content and watch again, please refresh your screen

In this interactive patient case video, you'll meet a 62-year-old man with advanced renal cell carcinoma (RCC) and follow his journey through selection of 1st- and 2nd-line therapies and managing associated toxicities. Along the way, you'll answer questions at key points, and engage with clickable resources to deepen your understanding of:

  • The different efficacy and safety profiles of targeted and immunotherapy treatments for RCC
  • How to implement targeted therapies and immunotherapies into treatment strategies for advanced RCC
  • Optimal sequencing of treatments
  • The cause of toxicities and strategies to improve tolerability and manage side effects whilst maintaining optimal efficacy

 

Clinical Takeaways

  • Current clinical practice for patients with advanced ccRCC is frontline combination of immunotherapy-VEGFR TKI for IMDC intermediate/poor-risk patients

  • Adverse events can generally be managed through dosing strategies, enabling the patient to remain on first-line therapy as long as possible

  • Switching to 2nd-line therapy should ideally be at the point of disease progression

Viktor Grünwald is a professor for Interdisciplinary Genitourinary Oncology at the University Hospital Essen in Essen, Germany. Professor Grünwald specialises in Internal Medicine and Medical Oncology. His main areas of research interest are in GU cancers, soft tissue sarcomas, head and neck cancers, with an emphasis on the academic development and translational research of immunotherapies in these indications.

Professor Grünwald graduated from the Medical School Hannover in 1998, after which he was appointed as a Private Lecturer and later professor for Haematology and Oncology at the same institution. He became professor for Interdisciplinary Genitourinary Oncology at the University Hospital Essen in 2018, thereby chairing the section for medical treatments of GU cancers.

Professor Grünwald served at the steering committee for genitourinary (GU) cancers (non-prostate) at the ESMO and ESMO ASIA Congress and was part of scientific committees of the International Kidney Cancer Symposium (EIKCS), German Cancer Congress (DKK) and the German Society for Haematology and Oncology (DGHO). He has chaired different working groups in academic organizations, such as the Central European Society of Anticancer Drug Research (CESAR) studies group, German Medical Oncology studies group (AIO) and German Cancer Society (DKG). His training activities include ESMO preceptorships and the ECCO-AACR-EORTC-ESMO workshop on methods in clinical cancer research (MCCR).

Prof. Viktor Grünwald has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Amgen, AstraZeneca, BMS, Eisai, Ipsen, Merck, MSD and Pfizer. 

Programme summary
  • clock Duration 15 MIN
  • clock Language(s) flag
Share this programme
This educational programme is supported by an Independent Educational Grant from Eisai Europe Limited.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

video Video
Oncology 
Recent advances in precision oncology and future implications

Two emerging and two established targets

Experts
Prof. David Hong
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Dec 2024

Educational programme supported by an Independent Educational Grant from Bayer.
publication Publication
Oncology 
Survey on the evolving role of the oncology nurse in the USA

Announcing the publication of survey results 

Experts
Nina Grenon, Natasha Pinheiro, Karen Waldrop, Brittni Prosdocimo
  • download Downloadable
    Resources
  • clock 10 MIN
  • calendar Dec 2024

Educational programme supported by an Independent Educational Grant from Bayer.
video Video
Oncology 
Elacestrant in ER+/HER2- metastatic breast cancer

An expert overview of the EMERALD subgroup analysis

Experts
Dr Virginia Kaklamani
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Dec 2024

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.
video Video
Oncology 
Systemic treatment options for patients with non-clear cell renal cell carcinoma (nccRCC)

Managing patients with nccRCC: guidelines, recommendations, and best practice

Experts
Prof. Laurence Albiges
Endorsed by
Urobel VZW | ASBL
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Dec 2024

Educational programme supported by an Independent Educational Grant from Eisai Europe Limited (“Eisai”). Eisai has had no input on the educational content of, or speakers involved in this programme. 
micro-learning Micro learning
Oncology 
Metastatic pancreatic ductal adenocarcinoma (PDAC): from diagnosis to treatment

Risk factors, diagnostic tools and treatment options for different patient groups

Experts
Prof. Efrat Dotan, Prof. Shubham Pant
Endorsed by
Digestive Cancers Europe
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Dec 2024

Educational programme supported by an Independent Educational Grant from Ipsen USA.
conference-update Conference update
Oncology 
Rezatapopt in TP53 Y220C mutated metastatic breast cancer: PYNNACLE phase 1/2 update

Exploring emerging treatment strategies presented at SABCS 2024

Experts
Prof. Frédérique Penault-Llorca, Dr Ecaterina E Dumbrava
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Dec 2024

This programme has been sponsored by PMV Pharma.